- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Thorvardur Halfdanarson: Access Is a Big Management Challenge in NETs
Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Thorvardur Halfdanarson, MD, associate professor of medicine and consultant in medical oncology, Mayo Clinic, outlines the biggest management challenges in neuroendocrine tumors (NETs).
Transcript
What are the biggest management challenges in neuroendocrine tumors?
One of the bigger management challenges is access to care and access to specialists, ad that doesn’t mean that everyone needs to be managed by a NET specialist, because they absolutely don’t. But, I think all NET patients should at least be given the option of visiting with a NET specialist just to discuss the natural history of the disease and to discuss treatments that might be available, and I think also, at the time of progression, we should really try to get these patients to see a NET specialist to discuss the different treatment options out there, including clinical trials.
So, I think access to NET specialists, because there are not that many of them, is still an issue. Insurance is an issue for some agents, high copayments for certain agents. We have to see how things play out with PRRT [peptide receptor radionuclide therapy] and insurance reimbursement. But, that would be access and the financial toxicity or direct cost to the patient would be the things on the top of my mind.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
